文章：

同种异体造血干细胞移植在当代费城染色体阳性B细胞急性淋巴细胞白血病治疗中的作用

Role of Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia in the Contemporary Era

原文发布日期：31 December 2024

DOI: 10.3390/cancers17010104

类型: Article

开放获取: 是

英文摘要：

The treatment of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-cell ALL) has seen substantial progress over the past two decades. The introduction ofBCR::ABL1tyrosine kinase inhibitor (TKIs) has resulted in dramatic improvements in long-term survival. Allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its curative potential, has always been an integral part of the treatment algorithm of Ph+ ALL. Recently, the approval of novel therapies such as blinatumomab, inotuzumab ozogamicin and chimeric antigen receptor T-cell (CAR-T) therapy in relapse and refractory (R/R) ALL have further improved outcomes of B-cell ALL. With potent TKIs and novel targeted therapy, the treatment guidelines for Ph+ ALL are evolving rapidly. Additionally, with improved tools for detecting measurable residual disease (MRD), there has been recent interest in redefining the role of allo-HSCT for some patients. In this context, we discuss the current evidence for the utilization of allo-HSCT for Ph+ ALL, focusing on novel therapies and MRD-directed care.

摘要翻译： 

费城染色体阳性B细胞急性淋巴细胞白血病（Ph+ B细胞ALL）的治疗在过去二十年中取得了显著进展。BCR::ABL1酪氨酸激酶抑制剂（TKIs）的应用显著改善了患者的长期生存率。异基因造血干细胞移植（allo-HSCT）因其治愈潜力，一直是Ph+ ALL治疗方案中不可或缺的一部分。近年来，针对复发难治性（R/R）ALL的新型疗法，如贝林妥欧单抗、奥加伊妥珠单抗以及嵌合抗原受体T细胞（CAR-T）疗法的获批，进一步改善了B细胞ALL的治疗效果。随着强效TKIs和新型靶向疗法的应用，Ph+ ALL的治疗指南正在迅速演变。此外，随着可测量残留病（MRD）检测工具的改进，近期学界开始重新评估allo-HSCT在某些患者中的作用。在此背景下，本文探讨了当前allo-HSCT在Ph+ ALL治疗中的应用证据，重点关注新型疗法和基于MRD指导的治疗策略。

原文链接：

Role of Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia in the Contemporary Era